Related Experiment Video
Updated: Jun 22, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Challenges and opportunities in neurometabolic disease treatment with enzyme delivery
David Begley1, Reinhard Gabathuler1, Gregory Pastores2
1Blood-Brain Barrier Group, King's College London, Strand, London, UK.
Introduction:
Neurometabolic disorders remain challenging to treat, largely due to the limited availability of drugs that can cross the blood-brain barrier (BBB) and effectively target brain impairment. Key reasons for inadequate treatment include a lack of coordinated knowledge, few studies on BBB status in these diseases, and poorly designed therapies.
Areas Covered:
This paper provides an overview of current research on neurometabolic disorders and therapeutic options, focusing on the treatment of neurological involvement. It highlights the limitations of existing therapies, describes innovative protocols recently developed, and explores new opportunities for therapy design and testing, some of which are already under investigation. The goal is to guide researchers toward innovative and potentially more effective treatments.
Expert Opinion:
Advancing research on neurometabolic diseases is crucial for designing effective treatment strategies. The field suffers from a lack of collaboration, and a strong collective effort is needed to enhance synergy, increase knowledge, and develop a new therapeutic paradigm for neurometabolic disorders.
Related Concept Videos
Gene Therapy
Lysosomal Hydrolases
Inborn Errors of Metabolism

